Setara Biosciences Raises $90M in Series A Financing to Advance Precision Medicines for Rare Genetic Diseases

San Diego, CA, October 30, 2026 (Business Wire) -- Setara Biosciences, a biotechnology company focused on developing precision medicines for rare genetic diseases, has announced a $90 million Series A financing round to advance its drug development programs targeting rare genetic disorders and related expansion indications. The financing will support the company's research and development activities, including the advancement of its precision medicine pipeline, clinical development programs, and efforts to address diseases with significant unmet medical needs.

Read full article here.